Compare IDEXX Laboratories, Inc. (IDXX) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Ferrari NV — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Ferrari NV trades at $371.66 (market cap $65.48B). The key difference: Ferrari NV is the larger of the two by market cap, and Ferrari NV pays a 1.14% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | RACE | |
|---|---|---|
Market Cap | $44.48B | $65.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $517.65 |
52-Week Low | $520.87 | $314.63 |
Enterprise Value | $45.38B | $66.69B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Ferrari (RACE) trades at $371.52, down 1.41% on the day, with a bullish technical signal from moving averages. The company exhibits strong fundamentals, including a 22.19% net income margin and consistent earnings beats, with Q2 2026 results due July 30, 2026. Recent news highlights institutional buying, a share buyback program, and the debut of its first electric vehicle, though the Luce model received mixed initial reception.
The outlook remains positive given analyst consensus, with a $467.50 price target implying significant upside. Key risks include execution on the EV transition and high valuation multiples. The stock presents a growth opportunity driven by brand strength and pricing power, but investors should weigh near-term volatility around earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
